Targeting Complement C3 and Factor B with siRNA: Concept to Clinic
Time: 10:15 am
day: Conference Day One
Details:
- Lessons learned from discovery and early preclinical complement inhibitor studies
- Using Complement Factor B inhibitors to target the alternative pathway
- Evaluating safety, tolerability, PK/PD in C3 and Factor B inhibitors to treat renal disease
